{
    "title": "Compassionate Access Act",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Compassionate Access Act''.\n\nSEC. 2. AVAILABILITY OF MARIHUANA FOR MEDICAL USE.\n\n    (a) Rescheduling.--\n            (1) Recommendation by hhs.--Not later than 180 days after \n        the date of enactment of this Act, the Secretary of Health and \n        Human Services, in consultation with the Institute of Medicine \n        of the National Academy of Sciences, shall submit to the \n        Administrator of the Drug Enforcement Administration a \n        recommendation to transfer marihuana from schedule I under \n        section 202 of the Controlled Substances Act (21 U.S.C. 812) to \n        a schedule under such section 202 other than schedule I.\n            (2) Final rule.--Not later than one year after the date of \n        enactment of this Act, the Administrator of the Drug \n        Enforcement Administration shall, taking into consideration the \n        recommendation under paragraph (1), issue a final rule to \n        transfer marihuana from schedule I under section 202 of the \n        Controlled Substances Act (21 U.S.C. 812) to a schedule under \n        such section other than schedule I.\n    (b) Cannabidiol.--\n            (1) In general.--Paragraph (16) of section 102 of the \n        Controlled Substances Act (21 U.S.C. 802) is amended--\n                    (A) by striking ``(16) The'' and inserting \n                ``(16)(A) The''; and\n                    (B) by adding at the end the following:\n            ``(B) Cannabidiol--\n                    ``(i) is excluded from the definition of marihuana \n                under subparagraph (A); and\n                    ``(ii) shall not be treated as a controlled \n                substance under this Act.''.\n            (2) Definition.--Section 102 of the Controlled Substances \n        Act (21 U.S.C. 802), as amended by paragraph (1), is further \n        amended by adding at the end the following:\n            ``(57) The term `cannabidiol' means the substance \n        cannabidiol, as derived from marihuana or synthetically \n        formulated, that contains not greater than 0.3 percent delta-9-\n        tetrahydrocannabinol on a dry weight basis.''.\n            (3) Cannabidiol determination by the states.--Section 201 \n        of the Controlled Substances Act (21 U.S.C. 811) is amended by \n        adding at the end the following:\n    ``(j) Cannabidiol Determination.--If a person grows or processes \nmarihuana for purposes of making cannabidiol in accordance with State \nlaw, the marihuana shall be deemed to meet the concentration limitation \nunder section 102(57), unless the Attorney General determines that the \nState law is not reasonably calculated to ensure that marihuana grown \nor processed for purposes of making cannabidiol meets such \nconcentration limitation.''.\n    (c) Regulation Under State Law.--\n            (1) In general.--In a State in which marihuana may be \n        prescribed by a physician for medical use under applicable \n        State law, no provision of the Controlled Substances Act (21 \n        U.S.C. 801 et seq.) or of the Federal Food, Drug, and Cosmetic \n        Act (21 U.S.C. 301 et seq.) shall prohibit or otherwise \n        restrict in such State in accordance with such State law--\n                    (A) the prescription of marihuana by a physician \n                for medical use;\n                    (B) an authorized patient under such State law from \n                obtaining, possessing, transporting, or using marihuana \n                for that patient's medical use;\n                    (C) a caregiver for an authorized patient from \n                obtaining, possessing, or transporting marihuana, as \n                authorized under such State law, for the medical use of \n                such authorized patient;\n                    (D) the legally recognized parent or guardian of a \n                minor who is an authorized patient from obtaining, \n                possessing, or transporting marihuana, as authorized \n                under such State law, for the medical use of such \n                minor;\n                    (E) an entity from producing, processing, or \n                otherwise manufacturing marihuana for medical use, as \n                authorized under such State law;\n                    (F) an entity from distributing marihuana for \n                medical use, as authorized under such State law;\n                    (G) a pharmacy or other health care provider from \n                dispensing marihuana to an authorized patient for \n                medical use, as authorized under such State law; or\n                    (H) a laboratory or other entity from performing \n                safety, quality, or efficacy testing of marihuana for \n                medical use, as authorized under such State law or \n                under Federal law.\n            (2) Cannabidiol.--Notwithstanding the exclusion of \n        cannabidiol from the definition of marihuana in section 102 of \n        the Controlled Substances Act (21 U.S.C. 802), as amended, and \n        section 5 of this Act, this subsection applies with respect to \n        cannabidiol, as defined in such section 102, to the same extent \n        and in the same manner as this subsection applies with respect \n        to marihuana.\n\nSEC. 3. RESEARCH INTO POTENTIAL MEDICINAL USES OF MARIHUANA.\n\n    (a) In General.--Not later than 180 days after the date of \nenactment of this Act, the Attorney General shall delegate \nresponsibility under section 303(f) of the Controlled Substances Act \n(21 U.S.C. 823(f)) for control over access to marihuana for research \ninto its potential medicinal uses to an agency of the executive branch \nthat is not focused on researching the addictive properties of \nsubstances. Such agency shall take appropriate actions to ensure that \nan adequate supply of marihuana is available for such medicinal \nresearch.\n    (b) Consideration of Other Research in Scheduling.--Research that \nis performed in a scientifically sound manner in a State where \nmarihuana or cannabidiol is legal for medical purposes, and in \naccordance with such State's law, but that does not use marihuana from \nfederally approved sources, may be considered for purposes of \nrescheduling marihuana under section 202 of the Controlled Substances \nAct (21 U.S.C. 812).\n\nSEC. 4. RELATION OF ACT TO CERTAIN PROHIBITIONS RELATING TO SMOKING.\n\n    This Act does not affect any Federal, State, or local law \nregulating or prohibiting smoking in public.\n\nSEC. 5. DEFINITIONS.\n\n    In this Act:\n            (1) Authorized patient.--The term ``authorized patient'' \n        means an individual using marihuana in accordance with a \n        prescription by a physician for medical use.\n            (2) Marihuana.--Except as provided in section 2(c)(2), the \n        term ``marihuana'' has the meaning given to such term in \n        section 102 of the Controlled Substances Act (21 U.S.C. 802), \n        as amended by section 2(b).\n            (3) Physician.--The term ``physician'' means a practitioner \n        of medicine, who--\n                    (A) graduated from a college of medicine or \n                osteopathy; and\n                    (B) is licensed to practice medicine by the \n                appropriate State board.\n            (4) Prescription.--The term ``prescription'' means an \n        instruction written by a medical physician in accordance with \n        applicable State law that authorizes the provision of a \n        medicine or treatment to a patient.\n            (5) State.--The term ``State'' includes the District of \n        Columbia, Puerto Rico, and any other territory or possession of \n        the United States."
}